The board of directors of Sino Biopharmaceutical Limited announced that "Lenvatinib Mesilate Capsule" (Brand name: Zewanxin), an antitumor drug developed by the Group, has obtained drug registration certificate granted by the National Medical Products Administration of the PRC, and is deemed to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs. Lenvatinib Mesilate Capsule is a kind of multi-target tyrosine kinase inhibitor which is applicable to unresectable hepatocellular carcinoma ("HCC") patients who have never received systemic therapy, and radioactive iodine ("RAI") refractory differentiated thyroid cancer patients. The approval for launch of this product can further strengthen the Group in the antitumor treatment sector and benefit tumor patients by relieving their financial burden.